Exploring Natural Compounds as Promising Matrix Metalloproteinase-2 inhibitors for Cancer Management: A Biocomputational Study

Akram Ahmed Aloqbi

Abstract


Background: Matrix metalloproteinase-2 (MMP2) plays a role in breaking down the components of the extracellular matrix, which allows cancer cells to advance and invade. Therefore, the inhibition of MMP2 shows potential as a promising strategy for treating cancer.

Methods: This study employed computational screening to identify MMP2 inhibitors from a collection of 2,405 natural compounds. GLXC-26716, the co-crystal ligand of MMP2, served as the positive control. Virtual screening was performed using PyRx 8.0 software to find molecules that might inhibit the active site of MMP2.

Results: The virtual screening process has identified five potential candidates: ZINC000000001412, ZINC000001612328, ZINC000001614079, ZINC000000119988, and ZINC0000000047553. These candidates were selected based on their strong binding affinities and interactions with MMP2. These compounds, which adhere to Lipinski's Rule of Five and have significant physicochemical properties, show promise as MMP2 inhibitors.

Conclusion: The finding of this study indicates a preliminary investigation into an innovative approach for managing cancer that inhibits the invasion and dissemination of cancer cells.

Keywords: Matrix Metalloproteinase-2; Natural compounds; Cancer; Virtual screening 


Full Text:

PDF

References


Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, et al. Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, (2004); 54(1): 8-29.

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, (2010); 141(1): 52-67.

Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology, (2007); 8(3): 221-233.

Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nature Reviews Immunology, (2004); 4(8): 617-629.

Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, (2006); 69(3): 562-573.

Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, (2009); 27(31): 5287-5297.

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, (1980); 284(5751): 67-68.

Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Critical Reviews in Biochemistry and Molecular Biology, (2007); 42(3): 113-185.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer, (2002); 2(3): 161-174.

Tauro M, Lynch CC. Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis. Cancers (Basel), (2018); 10(6): 185.

Fu Z, Xu S, Xu Y, Ma J, Li J, et al. The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. International Journal of Gynecological Cancer, (2015); 25(3): 356-362.

Shen W, Xi H, Wei B, Chen L. The prognostic role of matrix metalloproteinase 2 in gastric cancer: a systematic review with meta-analysis. Journal of Cancer Research and Clinical Oncology, (2014); 140(6): 1003-1009.

Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current Topics in Medicinal Chemistry, (2014); 14(16): 1923-1938.

Zhu H, Zhang Y, Li W, Huang N. A Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years. International Journal of Molecular Sciences, (2022); 23(24): 15961.

Jang C, Yadav DK, Subedi L, Venkatesan R, Venkanna A, et al. Identification of novel acetylcholinesterase inhibitors designed by pharmacophore-based virtual screening, molecular docking and bioassay. Scientific Reports, (2018); 8(1): 14921.

Sharma V, Jaiswal PK, Kumar S, Mathur M, Swami AK, et al. Discovery of Aporphine Analogues as Potential Antiplatelet and Antioxidant Agents: Design, Synthesis, Structure-Activity Relationships, Biological Evaluations, and in silico Molecular Docking Studies. ChemMedChem, (2018); 13(17): 1817-1832.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.

Reddy RA, Sai Varshini M, Kumar RS. Matrix Metalloproteinase-2 (MMP-2): As an Essential Factor in Cancer Progression. Recent Patents on Anti-Cancer Drug Discovery, (2023). doi:

2174/0115748928251754230922095544. Online ahead of print.

Chien MH, Lin CW, Cheng CW, Wen YC, Yang SF. Matrix metalloproteinase-2 as a target for head and neck cancer therapy. Expert Opinion on Therapeutic Targets, (2013); 17(2): 203-216.

Kamal MA, H MB, I JH, R SA, M SH, et al. Insights from the molecular docking analysis of EGFR antagonists. Bioinformation, (2023); 19(3): 260-265.

Sayed Murad HA, M MR, Alqahtani SM, B SR, Alghamdi S, et al. Molecular docking analysis of AGTR1 antagonists. Bioinformation, (2023); 19(3): 284-289.

Elaimi A, Hanadi MB, Almutairi A, Alniwaider RA, Abulkaliq MA, et al. Insights from the molecular docking analysis of GRP78 with natural compound inhibitors in the management of cancers. Bioinformation, (2023); 19(1):

-42.

I JH, Alsharif FH, Aljadani M, Fahad Alabbas I, Faqihi MS, et al. Molecular docking analysis of KRAS inhibitors for cancer management. Bioinformation, (2023); 19(4): 411-416.

Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. Frontiers in Pharmacology, (2019); 10: 1614.

George BP, Chandran R, Abrahamse H. Role of Phytochemicals in Cancer Chemoprevention: Insights. Antioxidants (Basel), (2021); 10(9): 1455.




DOI: http://dx.doi.org/10.62940/als.v11i3.3183

Refbacks

  • There are currently no refbacks.